--- title: "BRIEF: WuXi Biologics maintains full-year revenue guidance for up to 17% growth" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/288222579.md" description: "藥明生物宣佈截至 4 月 30 日獲得 69 個新整合項目，其中約三分之二來自歐美客户。公司維持全年營收增長 13%-17% 的指引，剔除匯率影響後預期增長 16%-20%。管理層對基於全球 CRDMO 平台及客户羣擴張的增長前景保持信心，預計未來三年營收復合年增長率達 20%。" datetime: "2026-06-01T06:05:47.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/288222579.md) - [en](https://longbridge.com/en/news/288222579.md) - [zh-HK](https://longbridge.com/zh-HK/news/288222579.md) generator: "portal-rs" --- # BRIEF: WuXi Biologics maintains full-year revenue guidance for up to 17% growth Drug development services company **WuXi Biologics (Cayman) Inc.** (2269.HK) **announced** on Sunday that it had secured 69 new integrated projects as of April 30, with approximately two-thirds originating from clients in the U.S. and Europe. The company maintained its full-year revenue growth guidance of 13% to 17%. Excluding foreign exchange fluctuations, revenue growth is expected to range between 16% and 20%. WuXi Biologics said it remains confident in its growth prospects, supported by its global contract research, development and manufacturing organization (CRDMO) platform and expanding customer base. Management expects revenue to achieve a compound annual growth rate of 20% over the next three years. Manufacturing operations are expected to serve as its primary growth driver, with management forecasting a three-year growth rate of approximately 30% for the segment. As more late-stage clinical and commercial manufacturing projects advance, the company expects a growing number of manufacturing programs to generate more than $100 million in annual revenue, further boosting its scale and profitability. WuXi Biologics shares opened higher on Monday and were trading at HK$34.22 at the midday break, up 2.64%. *By Lee Shih Ta* *To subscribe to Bamboo Works weekly free newsletter, click here* ### 相關股票 - [02269.HK](https://longbridge.com/zh-HK/quote/02269.HK.md) - [WXXWY.US](https://longbridge.com/zh-HK/quote/WXXWY.US.md) - [588250.CN](https://longbridge.com/zh-HK/quote/588250.CN.md) - [LABD.US](https://longbridge.com/zh-HK/quote/LABD.US.md) - [159615.CN](https://longbridge.com/zh-HK/quote/159615.CN.md) - [159102.CN](https://longbridge.com/zh-HK/quote/159102.CN.md) - [BIB.US](https://longbridge.com/zh-HK/quote/BIB.US.md) - [516500.CN](https://longbridge.com/zh-HK/quote/516500.CN.md) - [SBIO.US](https://longbridge.com/zh-HK/quote/SBIO.US.md) - [IBB.US](https://longbridge.com/zh-HK/quote/IBB.US.md) - [159892.CN](https://longbridge.com/zh-HK/quote/159892.CN.md) - [ARKG.US](https://longbridge.com/zh-HK/quote/ARKG.US.md) - [BBH.US](https://longbridge.com/zh-HK/quote/BBH.US.md) - [LABU.US](https://longbridge.com/zh-HK/quote/LABU.US.md) - [XLV.US](https://longbridge.com/zh-HK/quote/XLV.US.md) - [159849.CN](https://longbridge.com/zh-HK/quote/159849.CN.md) - [PBE.US](https://longbridge.com/zh-HK/quote/PBE.US.md) - [513060.CN](https://longbridge.com/zh-HK/quote/513060.CN.md) - [512290.CN](https://longbridge.com/zh-HK/quote/512290.CN.md) - [159506.CN](https://longbridge.com/zh-HK/quote/159506.CN.md) - [XBI.US](https://longbridge.com/zh-HK/quote/XBI.US.md) - [588130.CN](https://longbridge.com/zh-HK/quote/588130.CN.md) - [FBT.US](https://longbridge.com/zh-HK/quote/FBT.US.md) - [159859.CN](https://longbridge.com/zh-HK/quote/159859.CN.md) - [IXJ.US](https://longbridge.com/zh-HK/quote/IXJ.US.md) - [516930.CN](https://longbridge.com/zh-HK/quote/516930.CN.md) - [159837.CN](https://longbridge.com/zh-HK/quote/159837.CN.md) - [IBBQ.US](https://longbridge.com/zh-HK/quote/IBBQ.US.md) - [512010.CN](https://longbridge.com/zh-HK/quote/512010.CN.md) - [VHT.US](https://longbridge.com/zh-HK/quote/VHT.US.md) - [159316.CN](https://longbridge.com/zh-HK/quote/159316.CN.md) - [159992.CN](https://longbridge.com/zh-HK/quote/159992.CN.md) - [520880.CN](https://longbridge.com/zh-HK/quote/520880.CN.md) - [513120.CN](https://longbridge.com/zh-HK/quote/513120.CN.md) - [510660.CN](https://longbridge.com/zh-HK/quote/510660.CN.md) - [IHE.US](https://longbridge.com/zh-HK/quote/IHE.US.md) - [513700.CN](https://longbridge.com/zh-HK/quote/513700.CN.md) - [520690.CN](https://longbridge.com/zh-HK/quote/520690.CN.md) ## 相關資訊與研究 - [藥明生物向香港交易所提交次日披露申報，併發行 1,804,090 股新股](https://longbridge.com/zh-HK/news/298215084.md) - [09:28 ET LabCentral 的新項目 “The Loop” 向國際生物技術初創企業及合作組織直接提供來自美國市場的精選學習經驗](https://longbridge.com/zh-HK/news/298328140.md) - [實時市場：暑期結束迴歸常態，美股收跌](https://longbridge.com/zh-HK/news/298361334.md) --- > **免責聲明: 本文僅供參考，不構成任何投資建議。**